IP Library Granted Patent US 12,492,171
Granted Patent B2
US 12,492,171 · App. 17/652,022 · Granted Dec 9, 2025

Heterocyclic inhibitors of MCT4

Inventors: Kenneth Mark Parnell (Kaysville, UT); John McCall (Boca Grande, FL); Donna Romero (Chesterfield, MO)
Assignee: Vettore, LLC
C07D231/14A61K31/415A61K45/06A61P35/00C07C59/01C07D205/02C07D207/24C07D213/12C07D231/56C07D401/04C07D403/04C07D403/06C07D403/10C07D403/14C07D405/04C07D405/06C07D405/12C07D405/14C07D409/04C07D413/04C07D417/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,171
App. No.
17/652,022
Granted
Dec 9, 2025
Kind
B2
Abstract

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Claims (28)

1 . A method for treating idiopathic pulmonary fibrosis in a subject in need thereof, comprising administering to the subject a compound of structural Formula VIII:

or a salt thereof, wherein:

L is chosen from a bond and methylene;

Y is chosen from

R 2c is chosen from H, C 1 -C 4 alkoxy and C 1 -C 4 cycloalkoxy;

R 2d is chosen from null and C 1 -C 4 alkoxy;

R 2e is C 1 -C 4 alkyl;

n is 1 or 2;

R 4 and R 5 are independently chosen from C 1 -C 3 alkyl; and

R 6 is chosen from H and C 1 -C 4 alkyl.

2 . The method as recited in claim 1 , wherein n is 1.

3 . The method as recited in claim 1 , wherein L is a bond.

4 . The method as recited in claim 1 , wherein Y is

5 . A method for treating idiopathic pulmonary fibrosis in a subject in need thereof, comprising administering to the subject a compound of structural Formula XI:

or a salt thereof, wherein:

W is chosen from

m is 1, 2, or 3;

L is chosen from a bond and methylene;

Z is chosen from

n is 1 or 2;

R 4 and R 5 are independently chosen from C 1 -C 3 alkyl;

R 6 is chosen from H and C 1 -C 4 alkyl; and

R 9 is chosen from halo, amino, and C 1 -C 4 alkoxy.

6 . The method as recited in claim 5 , wherein W is

7 . The method as recited in claim 5 , wherein L is a bond.

8 . The method as recited in claim 5 , wherein n is 1.

9 . A method for treating idiopathic pulmonary fibrosis in a subject in need thereof, comprising administering to the subject a compound of structural formula:

or a salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2026
From: PARNELL, KENNETH MARK; MCCALL, JOHN; ROMERO, DONNA
To: VETTORE, LLC
Reel/Frame 074143/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2022
From: PARNELL, KENNETH MARK; MCCALL, JOHN; ROMERO, DONNA
To: VETTORE, LLC
Reel/Frame 060374/0534 →
Continuity (4)
Continuation 16222949 · Dec 17, 2018
Continuation 15839539 · Dec 12, 2017
Provisional Application 62433113 · Dec 12, 2016
Related Publication 20220251047A1 · Aug 11, 2022
References Cited (38)
US 3895026A · Palazzo · 1975 [cited by applicant]
US 5078780A · Moser · 1992 [cited by applicant]
US 5925768A · Barth · 1999 [cited by applicant]
US 8901314B2 · Wall · 2014 [cited by applicant]
US 9296728B2 · Mereddy · 2016 [cited by applicant]
US 10202350B2 · Parnell · 2019 [cited by examiner]
US 10214492B2 · Parnell · 2019 [cited by examiner]
US 11155522B2 · Parnell · 2021 [cited by examiner]
US 11292767B2 · Parnell · 2022 [cited by examiner]
US 11724989B2 · Parnell · 2023 [cited by applicant]
US 12187682B2 · Parnell · 2025 [cited by applicant]
US 20090042864A2 · Shia · 2009 [cited by applicant]
US 20110003874A1 · Guglielmotti · 2011 [cited by applicant]
US 20110160248A1 · Zhou · 2011 [cited by applicant]
US 20130190324A1 · Kompella · 2013 [cited by applicant]
US 20140378477A1 · Lisanti · 2014 [cited by applicant]
US 20160115146A1 · Draoui · 2016 [cited by applicant]
US 20160362378A1 · Parnell · 2016 [cited by applicant]
US 20180162822A1 · Parnell · 2018 [cited by applicant]
US 20190112274A1 · Parnell · 2019 [cited by applicant]
US 20190112275A1 · Parnell · 2019 [cited by applicant]
US 20210009524A1 · Parnell · 2021 [cited by applicant]
WO 2008060771 · 2008 [cited by applicant]
WO 2009109613 · 2009 [cited by applicant]
WO 2015188934 · 2015 [cited by applicant]
WO 2016192982 · 2016 [cited by applicant]
WO 2016201416 · 2016 [cited by applicant]
Tuder, et. al. “Lactate, a Novel Trigger of Transforming Growth Factor-↑ [cited by examiner]
Self et. al. “Romazarit. A potential disease-modifying antirheumatic drug” J. Med. Chem. 1991, 34, 772-777. DOI: 10.1021/jm00106a044 (Year: 1991). [cited by examiner]
Raiford et. al. “Formation of Pyrazolines From Unsymmetrically Substituted Dibenzalacetones” J. Org. Chem. Soc. 1940, 5, 6, 561-673. DOI: 10.1021/jo01212a004 (Year: 1940). [cited by examiner]
Dyson, et al., “Mir”, Chemistry of Synthetic Drugs, Moscow: Publishing House, pp. 12-19, (1964). [cited by applicant]
Pokrovskii, V. (1997), Popular Medical Encyclopedia, Ulianovsk: Knogochei Publishing House, 1997, p. 317. [cited by applicant]
Naim, M. et al., “Current status of pyrazole and its biological activities” J Pharm Bioallied Sci., 8(1):2-17, (2016). [cited by applicant]
U.S. Appl. No. 16/222,949; Examiner-Initiated Interview Summary, dated Nov. 9, 2021; 1 page. [cited by applicant]
U.S. Appl. No. 17/481,660; Non-Final Office Action, dated Oct. 14, 2022; 28 pages. [cited by applicant]
U.S. Appl. No. 17/481,660; Notice of Allowance, dated Mar. 22, 2023; 12 pages. [cited by applicant]
U.S. Appl. No. 18/337,313; Notice of Allowance, dated Aug. 28, 2024; 7 pages. [cited by applicant]
U.S. Appl. No. 18/958,610; Application as filed, dated Nov. 25, 2024; 106 pages. [cited by applicant]